Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324607 · ClinicalTrials.gov registry record · Phase 2
Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
A Phase 2 study, sponsored by Bastiaan Driehuys.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03324607 is a Phase 2 study that has completed, run by Bastiaan Driehuys. The registered enrollment target is 20 participants.
The verdict
NCT03324607, a Phase 2 study, has completed, sponsored by Bastiaan Driehuys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will be used as a new measure to determine change in function. The investigator anticipate these images will provide more specific information about lung disease than standard lung function tests in response to treatment.
Interventions
- DRUG hyperpolarized 129Xe gas MRI
- DRUG Bevespi Aerosphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-04-20 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324607
The ClinicalTrials.gov registry entry for NCT03324607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bastiaan Driehuys, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which hyperpolarized 129Xe gas MRI is the first listed.
NCT03324607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03324607 about?
NCT03324607 is a clinical study titled "Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI". The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will be used as a new measure to determine change in function. The...
What is the current status of trial NCT03324607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-04-20. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT03324607?
The interventions under investigation include: hyperpolarized 129Xe gas MRI (DRUG), Bevespi Aerosphere (DRUG).
Who is sponsoring clinical trial NCT03324607?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.